Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Accumulated Expenses (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other Accumulated Expenses for 13 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 44.31% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2025, down 44.31% year-over-year, with the annual reading at $11.2 million for FY2025, 44.31% down from the prior year.
  • Other Accumulated Expenses hit $11.2 million in Q4 2025 for Coherus Oncology, up from $7.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $20.0 million in Q4 2024 to a low of $3.5 million in Q4 2021.
  • Historically, Other Accumulated Expenses has averaged $11.2 million across 5 years, with a median of $11.0 million in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 71.33% in 2021 and later soared 204.52% in 2022.
  • Year by year, Other Accumulated Expenses stood at $3.5 million in 2021, then skyrocketed by 204.52% to $10.6 million in 2022, then decreased by 28.27% to $7.6 million in 2023, then skyrocketed by 162.56% to $20.0 million in 2024, then plummeted by 44.31% to $11.2 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CHRS at $11.2 million in Q4 2025, $7.1 million in Q3 2025, and $6.8 million in Q2 2025.